| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
The iodide transporter, NIS, is abundantly expressed in thyroid, as well as breast cancer and gastric cancer. Tumor-specific enhancement of its expression would make it possible to apply radio-iodide to target the tumors. We found significant induction of NIS expression by RXR agonists, and its enhancement by AKT inhibitors, in an in vitro model of gastric cancer. A number of translation inhibitors also induced the NIS expression in several cancer cell lines. Comprehensive analysis of miRNA expression in those cells suggested some miRNAs as potential NIS stimulators.
|
